Increase in the incidence of multidrug-resistant Gram-negative bacterial strains pose a significant threat to healthcare system worldwide. New antibiotics are necessary to combat particularly resitant pathogens. WHO’s global priority pathogens list was published in 2017 to promote research and development of new antibiotics, as part of WHO’s efforts to address growing global resistance to antimicrobial agents. Acinetobacter baumannii, Pseudomonas aeruginosa and carbapenem-resistant, third-generation cephalosporin-resistant Enterobacteriaceae were classified as highest priority pathogens requiring a new antibiotic treatment options. Cefiderocol is a novel parenteral siderophore cephalosporin that shows efficacy against listed Gram-negative bacteria. The results of the presented studies showed that cefiderocol has a strong antimicrobial effect against problematic strains that produce carbapenemases, such as KPC (K. pneumoniae carbapenemase) and B-class metallo-β-lactamases, including NDM-1 (New Delhi metallo-β-lactamase), as well as the ESBL-producing strains. In addition, it does not require the use of the β-lactamase inhibitor. The new agent demonstrates a favorable side effect profile. There is an urgent need to develop new antibiotics. Cefiderocol is a new antibiotic that has a potential to effectively combat particularly resistant bacteries such as carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, as well as carbapenem and 3rd generation cephalosporin-resistant Enterobacteriaceae.

Cefiderocol; cephalosporin; antibiotic resistance

WHO. Available at: http://apps.who.int/medicinedocs/documents/s23171en/s23171en.pdf. (accessed February 24, 2019.)

Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S et al. In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01454-17. doi: 10.1128/AAC.01454-17. Print 2018 Jan

Higgins PG, Dammhayn C, Hackel M et al. . Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233–8

Karah N, Sundsfjord A, Towner K et al. . Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat 2012; 15: 237–47.

Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826–36.

Heritier C, Poirel L, Nordmann P. Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii. Clin Microbiol Infect 2006; 12: 123–30.

Turton JF, Ward ME, Woodford N et al. . The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006; 258: 72–7.

Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2: S49–56.

Farra A, Islam S, Stralfors A et al. . Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int J Antimicrob Agents 2008; 31: 427–33.

Gupta V. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin Investig Drugs 2008; 17: 131–43.

Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25: 2–41.

Liaw SJ, Lee YL, Hsueh PR. Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and biofilm formation. Int J Antimicrob Agents 2010; 35: 126–30.

Akinobu Ito, Naoki Kohira, Samuel K. Bouchillon, Joshua West, Stephen Rittenhouse, Helio S. Sader et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, Volume 71, Issue 3, 1 March 2016, Pages 670–677

Akinobu Ito, Toru Nishikawa, Shuhei Matsumoto, Hidenori Yoshizawa, Takafumi Sato, Rio Nakamura et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. DOI: 10.1128/AAC.01405-16

Naoki Kohira, Joshua West, Akinobu Ito, Tsukasa Ito-Horiyama, Rio Nakamura, Takafumi Sato et al. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains DOI:10.1128/AAC.01695-15

Shun-Chung Hsueh, Yuarn-Jang Lee, Yu-Tsung Huang, Chun-Hsing Liao, Masakatsu Tsuji, Po-Ren Hsueh In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan J Antimicrob Chemother. 2019 Feb 1;74(2):380-386. doi: 10.1093/jac/dky425

Akinobu Ito, Toru Nishikawa, Merime Ota, Tsukasa Ito-Horiyama, Naoki Ishibashi, Takafumi Sato et al. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae Journal of Antimicrobial Chemotherapy, Volume 73, Issue 11, 1 November 2018, Pages 3049–3052

Takayuki Katsube PhD, Roger Echols MD, Juan Camilo, Arjona Ferreira MD, Heidi K. Krenz MD, Jolene Kay Berg MD et al. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impariment. J Clin Pharmacol. 2017 May;57(5):584-591. doi: 10.1002/jcph.841. Epub 2016 Nov 22.

James A.Karlowsky, Meredith A.Hackel, Masakatsu Tsuji, Yoshinori Yamano, Roger Echols, Daniel F.Sahm In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015 Int J Antimicrob Agents. 2018 Nov 22. pii: S0924-8579(18)30332-7. doi: 10.1016/j.ijantimicag.2018.11.007

Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother. 2017 Jun 1;72(6):1704-1708. doi: 10.1093/jac/dkx049. 1704–1708 AAC01041 Version Date: October 31, 2018

Sean M. Stainton, Marguerite L. Monogue, Masakatsu Tsuji, Yoshinori Yamano, Roger Echols,David P. Nicolau Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01040-18. doi: 10.1128/AAC.01040-18. Print 2019 Feb.

Simon Portsmouth, MD, David van Veenhuyzen, MBChB, Roger Echols, MD, Mitsuaki Machida, MS, Juan Camilo Arjona Ferreira, MD, Mari Ariyasu, BPharm et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial The Lancet Infectious Diseases Volume 18, Issue 12, P1319-1328, December 01, 2018 DOI:10.1016/S1473-3099(18)30554-1 Published: October 25, 2018